Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.
Nature Communications September 20, 2024 Václav Havel, Andrew C Kruegel, Benjamin Bechand et al. 18 citations
Ibogaine and its main metabolite noribogaine provide important molecular prototypes for markedly different treatment of substance use disorders and co-morbid mental health illnesses. However, these compounds present a cardiac safety risk and a highly complex molecular mechanism. We introduce a class of iboga alkaloids - termed oxa-iboga - defined as benzofuran-containing iboga analogs and...
DOI: 10.1038/s41467-024-51856-y (opens in new tab)
Full text (opens in new tab)
Drug discovery
Pain management
Drug safety